James Guss

James Guss is a clinician-researcher and psychotherapist who has been an active contributor to the modern clinical literature on psychedelic-assisted psychotherapy. His published and in‑progress work spans clinical trials, long‑term follow‑ups and qualitative analyses of patient experience, with a particular emphasis on psilocybin‑assisted psychotherapy for psychiatric and existential distress in patients with life‑threatening cancer. He has co‑authored reports documenting rapid and sustained reductions in anxiety, depression, loss of meaning and suicidal ideation following psilocybin treatment, and has contributed longitudinal follow‑up data and case series to clarify durability of benefit and lived experience after therapy.

Beyond clinical outcome studies, Guss has contributed to scholarship on therapist training, psychedelic integration and psychotherapeutic models for psychedelic work, including psychoanalytic and psycholytic perspectives. He has collaborated with clinician‑scientists working in PTSD, alcohol use and broader transdiagnostic mechanisms (for example, psychological flexibility), and has participated in multidisciplinary efforts linking qualitative and quantitative methods to inform best practices for preparation, dosing context and integration in clinical settings.